S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.85 (+2.26%)
NVDA   249.28 (+0.14%)
BABA   227.50 (+1.59%)
MU   57.66 (-0.03%)
AMD   50.93 (+2.33%)
F   9.15 (-0.22%)
DIS   144.25 (-0.60%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.85 (+2.26%)
NVDA   249.28 (+0.14%)
BABA   227.50 (+1.59%)
MU   57.66 (-0.03%)
AMD   50.93 (+2.33%)
F   9.15 (-0.22%)
DIS   144.25 (-0.60%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.85 (+2.26%)
NVDA   249.28 (+0.14%)
BABA   227.50 (+1.59%)
MU   57.66 (-0.03%)
AMD   50.93 (+2.33%)
F   9.15 (-0.22%)
DIS   144.25 (-0.60%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.85 (+2.26%)
NVDA   249.28 (+0.14%)
BABA   227.50 (+1.59%)
MU   57.66 (-0.03%)
AMD   50.93 (+2.33%)
F   9.15 (-0.22%)
DIS   144.25 (-0.60%)
Log in

NASDAQ:KURA - Kura Oncology Stock Price, Forecast & News

$12.77
-0.19 (-1.47 %)
(As of 01/17/2020 04:00 PM ET)
Today's Range
$12.70
Now: $12.77
$13.00
50-Day Range
$12.87
MA: $14.44
$15.94
52-Week Range
$12.65
Now: $12.77
$21.42
Volume19,025 shs
Average Volume279,991 shs
Market Capitalization$578.67 million
P/E RatioN/A
Dividend YieldN/A
Beta2.5
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KURA
CUSIPN/A
Phone858-500-8800

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.22 per share

Profitability

Net Income$-60,450,000.00

Miscellaneous

Employees43
Market Cap$578.67 million
Next Earnings Date3/3/2020 (Estimated)
OptionableOptionable

Receive KURA News and Ratings via Email

Sign-up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter.


Forbes mag says this strategy "like finding money in the street" (Ad)


And Reuters magazine calls this type of trading "the new baby boomer hobby." An anonymous trader -- living at the base of the Smoky Mountains -- just released a free report revealing a step-by-step system to generating an extra $5,000 per month in income thanks to this trading strategy. The report is free until Sunday.

Kura Oncology (NASDAQ:KURA) Frequently Asked Questions

What is Kura Oncology's stock symbol?

Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."

How were Kura Oncology's earnings last quarter?

Kura Oncology Inc (NASDAQ:KURA) posted its earnings results on Tuesday, November, 5th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.39) by $0.03. View Kura Oncology's Earnings History.

When is Kura Oncology's next earnings date?

Kura Oncology is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Kura Oncology.

What price target have analysts set for KURA?

8 brokers have issued 1 year price targets for Kura Oncology's stock. Their forecasts range from $22.00 to $30.00. On average, they expect Kura Oncology's stock price to reach $26.83 in the next year. This suggests a possible upside of 110.1% from the stock's current price. View Analyst Price Targets for Kura Oncology.

What is the consensus analysts' recommendation for Kura Oncology?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kura Oncology.

Has Kura Oncology been receiving favorable news coverage?

News headlines about KURA stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Kura Oncology earned a daily sentiment score of 2.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Kura Oncology.

Are investors shorting Kura Oncology?

Kura Oncology saw a decrease in short interest in the month of December. As of December 31st, there was short interest totalling 2,000,000 shares, a decrease of 10.7% from the December 15th total of 2,240,000 shares. Based on an average daily trading volume, of 283,700 shares, the days-to-cover ratio is currently 7.0 days. Currently, 4.9% of the shares of the stock are short sold. View Kura Oncology's Current Options Chain.

Who are some of Kura Oncology's key competitors?

What other stocks do shareholders of Kura Oncology own?

Who are Kura Oncology's key executives?

Kura Oncology's management team includes the folowing people:
  • Dr. Troy Edward Wilson, Chairman, CEO & Pres (Age 50)
  • Dr. Antonio Gualberto, Head of Devel. & Chief Medical Officer (Age 54)
  • Dr. Marc Grasso, CFO & Chief Bus. Officer
  • Mr. John Farnam, Chief Operating Officer
  • Mr. Pete De Spain, VP of Investor Relations & Corp. Communications

How do I buy shares of Kura Oncology?

Shares of KURA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Kura Oncology's stock price today?

One share of KURA stock can currently be purchased for approximately $12.77.

How big of a company is Kura Oncology?

Kura Oncology has a market capitalization of $578.67 million. The company earns $-60,450,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Kura Oncology employs 43 workers across the globe.View Additional Information About Kura Oncology.

What is Kura Oncology's official website?

The official website for Kura Oncology is http://www.kuraoncology.com/.

How can I contact Kura Oncology?

Kura Oncology's mailing address is 3033 SCIENCE PARK ROAD SUITE 220, SAN DIEGO CA, 92121. The company can be reached via phone at 858-500-8800 or via email at [email protected]


MarketBeat Community Rating for Kura Oncology (NASDAQ KURA)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  312 (Vote Outperform)
Underperform Votes:  274 (Vote Underperform)
Total Votes:  586
MarketBeat's community ratings are surveys of what our community members think about Kura Oncology and other stocks. Vote "Outperform" if you believe KURA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KURA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2020 by MarketBeat.com Staff

Featured Article: What is Forex?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel